HEAD-TO-HEAD COMPARISON

Compound Tirzepatide vs WegovyTirzepatide vs Semaglutide

Verdict: Compound Tirzepatide (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Wegovy (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Wegovy has a longer real-world track record and broader insurance coverage in some plans.

Side-by-side comparison

Compound Tirzepatide Wegovy
Active ingredient Tirzepatide Semaglutide
Manufacturer 503A / 503B pharmacies Novo Nordisk
FDA approval Not approved as finished product 2021
Indication Not an FDA-approved finished product. 503A compounding is restricted now that the FDA has declared the tirzepatide shortage resolved. Chronic weight management for adults with BMI 30+, or 27+ with at least one weight-related comorbidity
Starting dose Step 1 of 6 Step 1 of 5
Maintenance target 15 mg/week 2.4 mg/week
Titration length ~21 weeks ~17 weeks
Mean weight loss Same molecule as Mounjaro/Zepbound; outcomes track brand when correctly compounded ~14.9% mean at 68 weeks (STEP-1)
HbA1c reduction Same as branded tirzepatide ~1.6 pp (off-label in T2D)
Cost (US list) Historically $250 to $500 / mo during shortage ~$1,350 / mo US list
Insurance Not covered Patchy for obesity indication

Who should pick which

Switching between the two

Transitioning between tirzepatide and semaglutide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.

Open Tirzepatide Dose Calculator → Compare full titration schedules side by side

Frequently asked

Is Compound Tirzepatide better than Wegovy?
Compound Tirzepatide (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Wegovy (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Wegovy has a longer real-world track record and broader insurance coverage in some plans.
Can I switch from Compound Tirzepatide to Wegovy?
Transitioning between tirzepatide and semaglutide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Does Compound Tirzepatide produce more weight loss than Wegovy?
Compound Tirzepatide: Same molecule as Mounjaro/Zepbound; outcomes track brand when correctly compounded. Wegovy: ~14.9% mean at 68 weeks (STEP-1). Direct comparisons depend on dose, duration, and population studied; check the linked trial citations on each brand page for full context.
Why is Compound Tirzepatide priced differently from Wegovy?
Compound Tirzepatide costs Historically $250 to $500 / mo during shortage; Wegovy costs ~$1,350 / mo US list. Differences reflect manufacturer pricing strategy, FDA indication (obesity-labeled brands often face patchier insurance coverage than diabetes-labeled brands), and whether the product is a finished drug or a pharmacy compound.
Which is better for Type 2 diabetes, Compound Tirzepatide or Wegovy?
Both Compound Tirzepatide and Wegovy address T2D-relevant pathways via GLP-1 receptor activity. Trial HbA1c reductions: Compound Tirzepatide Same as branded tirzepatide; Wegovy ~1.6 pp (off-label in T2D).

Related

For research informational use only. Not medical advice. Wegovy is a registered trademark of its manufacturer. Consult a qualified healthcare provider for clinical decisions.